Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis

Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor- , in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study

(2011) G. R. Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Guidelines for reporting experiments involving animals: the ARRIVE guidelines

(2010) JC McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

Animal research: Reporting in vivo experiments: The ARRIVE guidelines

(2010) Carol Kilkenny et al.   BRITISH JOURNAL OF PHARMACOLOGY

Sym004: A Novel Synergistic Anti-Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy

(2010) M. W. Pedersen et al.   CANCER RESEARCH

Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry

(2010) T. R. Mikuls et al.   RHEUMATOLOGY

Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis

(2009) Peter C. Taylor et al.   Nature Reviews Rheumatology